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Background: Medulloblastoma is the most common malignant brain tumor in children. Genetic profiling has
identified four principle tumor subgroups; each subgroup is characterized by different initiating mutations, genetic
and clinical profiles, and prognoses. The two most well-defined subgroups are caused by overactive signaling in the
WNT and SHH mitogenic pathways; less is understood about Groups 3 and 4 medulloblastoma. Identification of
tumor subgroup using molecular classification is set to become an important component of medulloblastoma
diagnosis and staging, and will likely guide therapeutic options. However, thus far, few druggable targets have
emerged. G-protein coupled receptors (GPCRs) possess characteristics that make them ideal targets for molecular
imaging and therapeutics; drugs targeting GPCRs account for 30-40% of all current pharmaceuticals. While
expression patterns of many proteins in human medulloblastoma subgroups have been discerned, the expression
pattern of GPCRs in medulloblastoma has not been investigated. We hypothesized that analysis of GPCR expression
would identify clear subsets of medulloblastoma and suggest distinct GPCRs that might serve as molecular targets
for both imaging and therapy.
Results: Our study found that medulloblastoma tumors fall into distinct clusters based solely on GPCR expression
patterns. Normal cerebellum clustered separately from the tumor samples. Further, two of the tumor clusters
correspond with high fidelity to the WNT and SHH subgroups of medulloblastoma. Distinct over-expressed GPCRs
emerge; for example, LGR5 and GPR64 are significantly and uniquely over-expressed in the WNT subgroup of
tumors, while PTGER4 is over-expressed in the SHH subgroup. Uniquely under-expressed GPCRs were also observed.
Our key findings were independently validated using a large international dataset.
Conclusions: Our results identify GPCRs with potential to act as imaging and therapeutic targets. Elucidating
tumorigenic pathways is a secondary benefit to identifying differential GPCR expression patterns in
medulloblastoma tumors.
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Medulloblastoma is an embryonal tumor of the cerebel-
lum that accounts for 20% of all pediatric brain tumors
and is the most common cause of death from CNS ma-
lignancy in children [1]. Furthermore, survivors face a
multitude of long-term sequelae secondary to treatment;
exposing a developing brain to the cytotoxic therapies* Correspondence: sue-odorisio@uiowa.edu
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stated.that are currently offered can result in physical, neuro-
logical and intellectual disabilities [1-3]. Historically, me-
dulloblastoma tumors have been treated according to a
morphology-based classification system that divides tu-
mors into three principle histopathologic classes: classic,
desmoplastic/nodular and large cell/anaplastic (LCA)
[4]. The histopathological class informs prognosis, for
example tumors displaying LCA morphology generally
have the worst prognosis [4]. However, recent advances
have utilized genetic profiling to classify medulloblas-
toma tumors and these techniques have identified me-
dulloblastoma subgroups that differ in both molecular
and clinical profiles [5-7]. Various groups have identifiedl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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Whittier et al. Acta Neuropathologica Communications 2013, 1:66 Page 2 of 15
http://www.actaneurocomms.org/content/1/1/66between four and five potential subgroups [6,8-13]; how-
ever, a recent consensus conference determined that
evidence supported four distinct subgroups and acknowl-
edged the potential for multiple subtypes within each
subgroup [7]. The two most well-defined subgroups are
characterized by overactive signaling in the WNT and
Sonic hedgehog (SHH) mitogenic pathways. Less is known
about the underlying tumorigenesis mechanisms of the
remaining two tumor subgroups, Group 3 and Group 4;
however, specific genetic aberrations and gene expression
characteristics have been found, and epigenetic origins to
these tumors have been proposed [14-16]. These four
principle medulloblastoma subgroups differ in terms of
demographics, predominant histology, likely cell of origin,
DNA copy number aberrations and molecular markers
[5,7,17]. Importantly, the genetic profile has prognostic sig-
nificance leading investigators to urge translation of genetic
classification into clinical therapeutic trials [7,14,18,19].
Tumors of the WNT subgroup have the most favorable
outcomes and SHH tumors have an intermediate response
to current therapies. The recent development of small mol-
ecule inhibitors of the SHH pathway holds promise for the
treatment of these tumor subgroups [20,21]. Group 3 tu-
mors appear to have the worst prognosis using current
therapeutic approaches [5]; however, Groups 3 and 4 are
less well-characterized, both clinically and genetically,
resulting in a lack of potential targets that has hin-
dered the development of novel therapeutic strategies.
Identification of tumor subgroup using molecular classifi-
cation is expected to become an important component of
medulloblastoma diagnosis and staging in the near future.
Molecular classification will also likely be used to guide
therapeutic options, to measure response to therapy and to
provide early detection of relapse.
G-protein coupled receptors (GPCRs) are key regula-
tors and points of control in both the SHH and WNT
signal transduction pathways, as well as many other cell
signaling mechanisms [22]. GPCRs possess characteris-
tics that make them ideal targets for molecular imaging
and therapeutics; including that they are membrane-
bound, their ligands bind with high affinity and specificity,
and that the receptor-ligand complex is subsequently
endocytosed carrying the ligand into the tumor cell [23].
The utility of targeting GPCRs in medulloblastoma has
been demonstrated with the advent of somatostatin recep-
tor targeted imaging and therapy [24,25] and Octreoscans
are now able to differentiate medulloblastoma from low-
grade cerebellar tumors and scar tissue [25-28]. Molecu-
larly targeted imaging has the potential to provide in vivo
classification, and in vivo measurement of response to
treatment as well as early detection of relapse. Further-
more, molecularly targeted chemo- or radiotherapy has the
potential to decrease or alleviate long-term toxic effects of
external beam radiotherapy.While the molecular expression patterns of many
genes and proteins in medulloblastoma subgroups have
been discerned, subgroup-specific GPCR expression pat-
terns have not previously been investigated. A subset of
GPCRs appear on commonly used gene chips, such as the
Affymetrix U133 chip; however these chips do not allow
for the detection of under-expressed genes [29,30]. Our
approach, using quantitative GPCR arrays (Taqman), al-
lows for the assessment of both over- and under-expressed
GPCRs.
The aim of this study was to discover G-protein coupled
receptors that could serve as targets for imaging and
therapeutic agents in medulloblastoma, and we have suc-
cessfully identified potential receptor targets. Elucidating
tumorigenic and potentiating mechanisms in medulloblas-
toma subtypes has been a secondary benefit to our study.
Methods
Human tumor cohort
Tumors analyzed for GPCR expression consisted of snap-
frozen tumor tissues from 41 medulloblastomas, repre-
senting primary surgical resection tissue. Normal pediatric
cerebellum was used as control tissue. Both specimen
types were acquired from the Cooperative Human Tissue
Network (Columbus, OH), The Queensland Children’s
Tumour Bank (Queensland, AUS), The Children’s Cancer
Research Unit at the Children’s Hospital at Westmead
(Westmead, AUS), the Knight Cancer Institute Biolibrary
at Oregon Health and Sciences University (Portland, OR)
and from patients of the University of Iowa Hospitals and
Clinics (UIHC) Children’s Hospital. Basic clinical data in-
cluding age and sex were also obtained. The histopatho-
logical reports were acquired with the majority of tumor
samples and more extensive pathology reports including
cytogenetics were available for some patients. UIHC speci-
mens were acquired under an Institutional Review Board
(IRB) approval. Specimens acquired from other sources
were de-identified and use of these tissues was declared
“Not Human Research” by the University of Iowa IRB.
RNA isolation and GPCR expression arrays
RNA was isolated from snap-frozen tumor tissue using
the PerfectPure RNA Tissue Kit (5Prime); the quantity
and quality of RNA was evaluated using a Nanodrop
1000 Spectrophotometer (Thermo Fischer Scientific)
and an Agilent 2100 Bioanalyzer. RNA of sufficient qual-
ity was defined as having an RNA Integrity Number
(RIN) of at least 6 on a scale of 1–10; RINs in the 8–9.5
range were most commonly seen. The High-Capacity Re-
verse Transcription Kit (Applied Biosystems) was used to
convert the isolated RNA to cDNA. The resultant cDNA
of each tumor sample was then applied to a TaqMan Hu-
man GPCR Array (Applied Biosystems) which contains
380 TaqMan Gene Expression Assays arranged in a 384
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array was subsequently run on a 7900HT Fast Real-Time
PCR System (Applied Biosystems) and the resulting data
was analyzed using the SDS/Relative Quantification
Manager v.1.2 and the DataAssist v.3.0 software packages
(both Applied Biosystems).
Statistical analysis
Statistical calculations were performed by the DataAssist
(v3.0; Applied Biosystems) software. Maximum allow-
able CT value was set at 40.0 and these values were
included. The global normalization method was employed
[31]. All p-values were adjusted using the Benjamin-
Hochberg False Discovery Rate to correct for multiple
testing and the occurrence of false positives. Heat maps
are the result of unsupervised hierarchical clustering per-
formed by DataAssist. Distances between tumor samples
were calculated for clustering based on the ΔCT values
using Pearson’s Correlation; complete linkage was used as
the clustering method.
Histology
Formalin-fixed paraffin embedded (FFPE) tissues were
obtained from the previously mentioned tissue banks in
the form of 4 μm thick sections on slides. These tissues
were routinely stained with hematoxylin and eosin (HE)
to determine architectural and morphological features, in-
cluding desmoplasia, nodular formation, and large-cell/
anaplastic features. Dominant histologic category was de-
termined by a neuropathologist.
Immunohistochemistry
On cases in which FFPE material was available, sub-
grouping was accomplished following an immunohis-
tochemical method established at St. Jude Children’s
Research Hospital that uses immunoreactivity patterns to
four antibodies (β-catenin, YAP1, GAB1 and filamin A)
to categorize tumors into the WNT and SHH subgroups
and Non-WNT/SHH tumors [32]. In this study, the
SHH and WNT subgroups, and Non-SHH/WNT tumors
were identified via immunoreactivity patterns to two of
these markers: β-catenin (Abcam #ab16051) and YAP1
(Santa Cruz #sc-101199).
Antigen unmasking of paraffin sections was performed
(citrate buffer, pH 6) in a decloaker and endogenous
peroxidase activity was quenched with 3% hydrogen
peroxide. Sections were incubated with the primary
antibody (β-catenin at 1:2000; YAP1 at 1:1000) for 60 min
(β-catenin) or 30 minutes (YAP-1) and then incubated
with DAKO Mouse Envision HRP System reagent for 30
minutes for β-catenin or 15 minutes for YAP1. Slides were
developed with DAKO DAB plus for 5 min followed by
DAB Enhancer for 3 minutes before counterstaining with
hematoxylin.Fluorescence in situ hybridization (FISH)
In cases in which there was sufficient material, FISH to
determine C-MYC and/or N-MYC amplification was
performed. The DNA probes C-MYC BAP and N-MYC/
CEP2 (Abbott Molecular) were utilized. The sections
with C-MYC copy number gains were sequentially probed
with a CEP8 probe to further assess chromosome 8 copy
number gains vs specific C-MYC amplification. The pro-
tocols for FFPE slide preparation and hybridization were
as per manufacturer’s specifications. Briefly, after depara-
ffinizing, enzyme-pretreating and fixing the sections, the
hybridizations were performed on a ThermoBrite (Abbott
Molecular) programmed for melt temperature at 85°C
and time for 2 minute. After overnight hybridization at
37°C, the slides were washed in 0.4XSSC/0.3% NP-40
for 2 minutes at 73°C and in 2XSSC/0.1% NP-40 for
1 minute at room temperature. The slides were then
counterstained with DAPI. The slides were analyzed and
images acquired using CytoVision computerized imaging
system (Leica, USA).
Independent correlation of GPCR expression patterns
Three independent previously published gene expression
[8,10-12] datasets were analyzed using the R2 software
(http://r2.amc.nl). Expression patterns of LGR5, GPR64,
PTGER4, FZD2 and F2R were compared according
to the four medulloblastoma subgroups. Differential ex-
pression of these candidate genes was assessed using




RNA from 41 human medulloblastoma tumors and four
normal human cerebellum specimens were subjected to
qPCR analysis of GPCR expression levels. Clusters of
medulloblastoma tumors emerged based solely on their
GPCR expression patterns (Figure 1; Additional file 1:
Figure S1 includes the GPCR loci). Unsupervised hier-
archical clustering of all 45 samples revealed varying
numbers of groups, depending on the level of associ-
ation. Two clusters of tissue samples emerged at the
lowest level of association: one cluster of 14 tumors des-
ignated cluster “E” (Figure 1b and Table 1) and a second
cluster including the remaining tumor 27 samples, as
well as the four normal cerebellar controls.
The next level of association split this cluster of 31
specimens (27 tumors and 4 controls) into two further
clusters: 1) four tumor samples (cluster “D” in Figure 1b
and Tables 1 and 2) four cerebellar control samples plus
one tumor sample (Controls B, C, D, E and MB 40). The
other 21 tumors could be further divided into three clus-
ters designated “C” (n = 10), “B” (n = 4), and “A” (n = 7)
in Figure 1b and Table 1. One tumor sample associated
Figure 1 GPCR expression patterns delineate distinct groups of medulloblastoma tumors. The heat map represents GPCR expression levels
in 41 medulloblastoma tumors compared to normal pediatric cerebella (a). Red color indicates low CT on qPCR, corresponding to high RNA
expression; blue is high CT and low RNA expression. Control cerebella (Controls B, C, D, E) are outlined in the black box. This heat map displays
the results of unsupervised hierarchical clustering performed by DataAssist (v3.0; Applied Biosystems) software. Presented in this heat map are
those GPCRs that were over- or under-expressed, as compared to control cerebellum, at a p ≤ 0.10 level. An enlarged image of the clustering
stems, as well as the resultant tumor groups is seen in (b). Distances between tumor samples were calculated for clustering based on the ΔCT
values using Pearson’s Correlation; complete linkage was used as the clustering method. Groups (A-E) of medulloblastoma tumors have emerged
based solely on their GPCR expression patterns (b). Subsequent immunohistochemical subtyping of the medulloblastoma samples identified
tumors of the SHH, WNT and Non-WNT/SHH subgroups (Figure 2, Table 2). The SHH- and WNT-subgroup tumors clustered tightly together on
the GPCR expression heat map. Red color indicates tumors identified as belonging to the SHH subgroup, blue indicates WNT subgroup tumors
and green indicates tumors identified as Non-WNT/SHH. FFPE slides not available for classification for those medulloblastoma samples in black.
Whittier et al. Acta Neuropathologica Communications 2013, 1:66 Page 4 of 15
http://www.actaneurocomms.org/content/1/1/66
Table 1 GPCR expression levels by linkage analysis clusters, compared to normal cerebella
Cluster “A” Cluster “B” Cluster “C” Cluster “D” Cluster E”
(n = 7) (n = 4) (n = 10) (n = 4) (n = 14)
Fold change p-value Fold change p-value Fold change p-value Fold change p-value Fold change p-value
FZD2 25 0.01 27 0.04 16 0.01 45 0.01 4.5 0.05
RPLP0 15 0.01 7.8 0.32 9.8 0.01 28 0.01 2.9 0.19
EDG4 25 0.01 22 0.04 22 0.01 20 0.03 7.8 0.04
PTGER4 14 0.01 2.0 0.43 5.7 0.01 2.9 0.30 1.1 0.90
GPR126 17 0.01 13 0.21 15 0.01 0.67 0.76 6.1 0.08
OR2C3 0.035 0.01 0.026 0.29 0.0076 0.01 0.12 0.49 1.1 0.89
FKSG83 0.010 0.01 0.037 0.22 0.30 0.26 0.61 0.69 2.7 0.31
F2R 73 0.01 54 0.04 55 0.02 29 0.03 15 0.03
DRD2 75 0.01 24 0.10 17 0.02 19 0.04 4.9 0.13
GPR142 0.078 0.60 undetectable 5.E-03 0.51 0.81 1.0 0.99 0.23 0.52
OPRM1 0.57 0.74 0.0028 0.22 0.0063 0.01 0.0032 0.23 0.00050 3.E-03
GPR147 0.059 0.15 0.011 0.29 0.0056 0.01 0.035 0.10 0.00050 5.E-04
GPR62 2.2 0.30 7.3 0.07 14 0.01 10 0.15 3.1 0.08
GPR153 3.3 0.10 8.7 0.21 8.5 0.01 0.50 0.24 3.0 0.04
PPYR1 0.59 0.63 0.033 0.21 0.030 0.01 0.47 0.37 1.2 0.82
EDG8 0.053 0.10 0.080 0.29 0.11 0.01 0.15 0.37 0.50 0.19
GPR160 2.4 0.19 5.9 0.22 12 0.01 1.2 0.90 1.4 0.61
SSTR3 0.40 0.61 0.13 0.49 0.068 0.01 0.72 0.62 0.99 0.99
GPR10 0.15 0.19 0.11 0.38 0.082 0.01 0.23 0.20 0.58 0.36
EDG7 0.42 0.48 0.12 0.56 0.12 0.03 0.0079 0.01 0.032 1.E-03
GRM6 19 0.22 326 0.29 248 0.02 1539 0.01 79 0.01
CCKBR 0.28 0.60 0.12 0.29 0.039 0.03 0.0028 0.01 0.010 0.01
OPRK1 0.29 0.49 1.0 1.0 0.21 0.20 0.0027 0.01 0.046 0.03
CHRM4 19 0.55 5.1 0.23 4.8 0.11 74 0.01 3.3 0.21
OPRD1 11.8 0.29 3.3 0.76 1.9 0.40 344 0.01 0.85 0.88
LGR5 0.50 0.71 0.83 0.95 0.45 0.55 117 0.01 0.22 0.17
GPR123 0.048 0.19 0.034 0.23 0.031 0.02 0.0041 0.15 0.0016 4.E-04
NTSR2 0.023 0.03 0.030 0.23 0.080 0.03 0.0030 0.04 0.0056 5.E-04
TRBV5 0.083 0.14 0.077 0.22 0.10 0.08 2.0 0.79 0.0051 3.E-03
ADORA1 0.83 0.91 0.28 0.32 0.14 0.14 3.0 0.33 0.019 3.E-03
ADRA1A 0.27 0.38 0.066 0.23 0.024 0.03 0.0082 0.19 0.0088 0.01
GRM4 0.13 0.30 0.11 0.32 0.037 0.06 0.0043 0.03 0.0048 0.01
HTR5A 0.074 0.17 0.12 0.29 0.17 0.15 0.0091 0.03 0.017 0.01
GPR84 0.20 0.19 0.39 0.54 0.10 0.05 0.045 0.04 0.043 0.01
GPR39 0.11 0.20 0.0068 0.05 0.015 0.02 0.0041 0.03 0.0058 0.01
GPR77 1.0 0.99 0.47 0.54 0.85 0.85 0.14 0.51 0.041 0.01
GPR37L1 0.049 0.19 0.057 0.22 0.080 0.11 0.0054 0.19 0.0058 0.01
GPR63 1.5 0.77 0.18 0.53 0.075 0.10 1.4 0.82 0.012 0.01
GPR75 0.48 0.43 0.15 0.21 0.22 0.11 0.13 0.06 0.029 0.01
OR2A4 0.51 0.50 5.7 0.22 3.7 0.08 2.1 0.51 3.3 0.01
CD97 4.6 0.12 1.4 0.68 1.8 0.11 1.5 0.67 0.27 0.01
* Fold-change <1 indicates decreased expression compared to normal cerebellum; all fold-change levels rounded to two significant digits. Significant fold-changes
(p ≤ 0.01) indicated indicated in bold.
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Table 2 Immunohistochemical groupings of medulloblastoma tumors
β-catenin
Nuclear + Cytoplasmic Cytoplasmic
YAP1
Positive MB5, MB8, MB15, MB35 MB2, MB6, MB24, MB34, MB38
WNT SHH
Negative
MB1, MB3, MB4, MB7, MB13, MB14, MB18, MB25, MB26, MB27, MB28,
MB29, MB30, MB31, MB32, MB33, MB36, MB37, MB39, MB40, MB41, MB42
Non-WNT/SHH
* MB28 and MB37 displayed rare nuclei that were weakly positive for YAP1; both were considered negative for YAP1 immunoreactivity.
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ples display a GPCR expression profile that is very dis-
tinct from each of the five clusters of medulloblastoma
tumors (clusters “A,” “B,” “C,” “D” and “E;” Figure 1).
GPCR expression levels in linkage analysis clusters
The fold-change in expression of GPCRs between tumor
and normal tissue was evaluated in the distinct clus-
ters (A-E) of medulloblastoma. Table 1 summarizes the
GPCRs that were over- or under-expressed at a significant
level (p≤ 0.01) in one or more clusters compared to nor-
mal cerebella. No GPCRs were significantly altered in all
five clusters at this significance level.
Among the 380 GPCRs probed, nine GPCRs displayed
significantly altered expression in cluster “A;” seven were
over-expressed, ranging from 14-fold (PTGER4) to 75-fold
(DRD2) expression, while two (OR2C3 and FKSG83) were
under-expressed, compared to normal cerebella (Table 1).
One GPCR (GPR142) exhibited significantly altered
expression in cluster “B;” GPR142 expression was un-
detectable in this cluster. There were no significant alter-
ations in expression levels of GPR142 in the other clusters,
compared with normal cerebella.
Expression of 15 GPCRs was significantly altered in clus-
ter “C;” six of these GPCRs were common between clusters
“A” and “C” and two other GPCRs were common between
clusters “C” and “E.” In cluster “C,” over-expression was
seen in eight of the GPCRs, ranging from 5.7-fold
(PTGER4) to 22-fold (EDG4) expression; under-expression
in seven GPCRs ranged from 0.01-fold (OR2C3, OPRM1
and GPR147) to 0.11-fold (EDG8) compared to normal
cerebellum (Table 1).
Nine GPCRs displayed significantly altered expression
levels in cluster “D;” two of these GPCRs were common
to both clusters “A” and “C” while three other GPCRs
were common to cluster “E” (Table 1). Six of the nine
GPCRs with altered expression levels in cluster “D” ex-
hibited over-expression, ranging from 28-fold (RPLP0)
to 1500-fold (GRM6).
Twenty GPCRs had significantly altered expression in
cluster “E” (Table 1). Two of these GPCRs were com-
mon to cluster “C” and three were common to cluster
“D.” Of the 20 GPCRs with altered expression levels incluster “E,” only two were over-expressed (GRM6 and
OR2A4) while the other 18 were under-expressed, as
compared to normal cerebella.
Immunohistochemical analysis and categorization
Formalin-fixed, paraffin-embedded (FFPE) blocks of
tumor tissue were available for thirty of the tumors that
had been assayed for GPCR expression levels. Immuno-
reactivity was determined by two independent University
of Iowa pathologists, with any differences being resolved
between two readers. Additionally, sections of medulloblas-
toma tumor samples obtained through the Queensland
Children’s Tumour Bank (MB30 – MB41) were separately
probed for immunoreactivity to the same antibodies at
Pathology Queensland (Australia). These sections were
read by an independent Pathology Queensland path-
ologist; therefore, for these samples (MB30- MB41),
there are three independent readers. A high level of agree-
ment was observed between the two different laboratories.
Tumors were classified based on immunoreactivity
patterns, as shown in Table 2. Immunoreactivity to YAP1
has been shown to differentiate WNT and SHH tumors
from Non-WNT/SHH (Groups 3 and 4) tumors [32]. Im-
munoreactivity to YAP1 was found in nine out of 31 tu-
mors (Table 2). Nuclear immunoreactivity to β-catenin is a
well-established method for the identification of WNT –
driven medulloblastoma tumors [5,32]. Nuclear β-catenin
staining in less than 2% of tumor nuclei was considered
sporadic and these samples were read as negative for nu-
clear β-catenin staining [32]. Four tumor samples displayed
nuclear β-catenin staining. All four of these tumors positive
for nuclear β-catenin also displayed YAP1 immunoreactiv-
ity, and have therefore been classified as a WNT subtype
medulloblastoma (Table 2).
Combining the findings from the immunoreactivity
patterns to YAP1 and β-catenin provides a method of
differentiating the WNT, SHH and non-WNT/SHH sub-
groups of tumors. A combination of YAP1 immunoreactiv-
ity and nuclear β-catenin staining (Figure 2d, h) segregated
the WNT subgroup (n = 4; 13%), as shown in Table 2.
Positive YAP1 staining without nuclear β-catenin staining
(Figure 2e, i) indicated the SHH subgroup (n = 5; 17%);
non-WNT/SHH subgroups were characterized by a lack of
Figure 2 Examples of immunohistochemical (IHC) staining in human medulloblastoma tumors. A method for differentiation of molecular
medulloblastoma subgroups using immunoreactivity to four markers was establish by Ellison DW et al. in 2011 [32]. The H&E, β-catenin and YAP1
staining of three representative medulloblastoma tumor samples is shown in panels a – i. MB 15 (a) displays classical morphology, MB 6 (b) is an
example of desmoplastic morphology and includes extensive focal nodularity, and MB 3 (c) displays anaplastic characteristics. MB 15
demonstrated nuclear and cytoplasmic immunoreactivity to β-catenin (d) and was positive for YAP1 staining (g), characterizing it as belonging to
the WNT molecular subgroup. Conversely, MB 6 displayed only cytoplasmic β-catenin staining (e), and was positive for YAP1 (h), indicating that
it is of the SHH subgroup. Lastly, MB 3 is cytoplasmically immunoreactive for β-catenin (f) and negative for YAP1 (i) staining, thus placing this
tumor in the Non-WNT/SHH category. Staining for the above markers has been evaluated in 30/41 medulloblastoma tumors. The scale bars in
panels a - i represent 20 μm; the scale bar in the inset images in each panel represents 100 μm.
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n = 22; 70%). The remaining 10 tumors were not classified
due to lack of FFPE tissue for the performance of immuno-
histochemical analysis. Our observed distribution of tu-
mors into the subgroups closely aligns with previously
published distributions in larger cohorts [5].
Medulloblastoma subgroups
WNT pathway medulloblastomas
The WNT pathway medulloblastomas (n = 4) were identi-
fied by a combination of positive YAP1 staining, as well as
nuclear and cytoplasmic immunoreactivity to β-catenin
(Figure 2, Table 2). All WNT tumors displayed classic
histopathology, characterized by sheets of monomorphic
cells with hyperchromatic nuclei and a high nuclear:
cytoplasmic ratio (Figure 2) [4]. C-MYC and N-MYC
amplification was probed using fluorescent in-situ
hybridization (FISH); the N-MYC signal was normal in all
four WNT subgroup tumors and no C-MYC amplification
was observed, though two WNT tumors displayed
increased C-MYC signal due to gains of chromosome 8
(Additional file 2: Table S1). Of the four WNT tumors,
50% were from male patients, and the age range for all
tumors was 5 to 17 years.The WNT tumors (MB5, MB8, MB15, MB35) tightly
clustered together (Figure 1, Table 2) and completely cor-
relate to linkage analysis cluster “D” (Figure 1b). Aside
from each other, the WNT tumors were most closely
associated with the normal cerebellar control samples. To
determine GPCR expression patterns specifically in this
subgroup, the WNT tumors were grouped together and
the fold-change in expression level of each receptor, as
compared to normal controls, was assessed.
The expression levels of 26 GPCRs, out of the 380 recep-
tors probed, were significantly (p ≤ 0.05) altered in WNT
tumors compared to expression levels in normal cerebella
(Additional file 3: Table S2). Of these 26 GPCRs, 12 were
expressed at a significantly lower level than in normal
cerebella, while 14 were over-expressed (Additional file 3:
Table S2). The levels of under-expression ranged from
0.003-fold (OPRK1) to 0.07-fold (RHO), while the levels of
over-expression ranged from 8.8-fold (MRGPRE) to 2200-
fold (GPR64). Four of the over-expressed GPCRs within
the WNT subgroup (FZD2, F2R, EDG4 and RPLP0) were
also over-expressed to a significant level within the SHH
subgroup tumors and the Non-WNT/SHH tumors. Five
GPCRs (EDG7, CCKBR, GRM4, NTSR2 and GPR84) were
significantly under-expressed in the WNT subgroup and
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significantly over-expressed in both groups.
SHH pathway medulloblastomas
Positive immunoreactivity to YAP1, combined with non-
nuclear β-catenin staining identified tumors of the SHH
subgroup (n = 5; Figure 2, MB6; Table 2). One SHH
subgroup tumor displayed classic histopathology, two
tumors exhibited desmoplasia with nodularity and one
tumor had anaplastic features. One tumor was classified
as having complex histopathology with multiple mor-
phological features. C-MYC and N-MYC FISH data were
available for four of the five SHH tumors; all four of
these tumors displayed normal C-MYC and N-MYC
signals (Additional file 2: Table S1). Within the SHH
subgroup, two patients were female, two were male; age
and gender of the patient were unknown for one tumor.
Ages of the patients ranged from 1.0 to 2.5 years.
The SHH-subgroup of tumors corresponds to the link-
age analysis cluster “A” established by GPCR expression
patterns (Figure 1). All five SHH subgroup tumors
(MB2, MB6, MB24, MB34 and MB38) clustered
together in a grouping of seven tumor samples; one Non-
WNT/SHH tumor sample (MB36) and one tumor sample
for which FFPE tissue was not available for categorization
(MB19) also clustered in this group (Figure 1).
Seven GPCRs in the SHH subgroup displayed signifi-
cantly altered expression levels when compared to
normal cerebellum (p ≤ 0.05; Additional file 3: Table S2).
Six of these altered GPCRs demonstrated over-expression,
ranging from 14-fold (RPLP0) to 72-fold (F2R) expres-
sion, while one (FKSG83) displayed under-expression
(0.01-fold). As discussed above, four GPCRs were also
over-expressed to a significant level within all three
(WNT, SHH, Non-WNT/SHH) categorized tumor groups
(FZD2, RPLP0, EDG4 and F2R). There were no GPCRs
that were significantly altered and common to both the
SHH and WNT, but not the other subgroups. One GPCR
(GPR126) was altered exclusively in the SHH and the
Non-WNT/SHH subgroups and two GPCRs (PTGER4
and FKSG83) were uniquely altered only in the SHH
subgroup tumors.
Non-WNT/SHH medulloblastomas
A lack of YAP1 immunoreactivity in medulloblastoma
tumors is indicative of the Non-WNT/SHH subgroup
(encompassing both Groups 3 and 4 [32]). Twenty-two
tumors were negative for YAP1 (Figure 2, MB3; Table 2).
Moreover, all 22 of these tumors also lacked nuclear
β-catenin immunoreactivity (Figure 2f ), as would be
expected for Non-WNT/SHH tumors. Of these 22 tumors,
10 displayed purely classic histopathology, four tumors had
classic histopathology along with areas demonstrating
anaplastic features, three tumors displayed desmoplastic ornodular/desmoplastic qualities and five tumors exhibited
purely large-cell, anaplastic or anaplastic morphology
(Additional file 2: Table S1). C-MYC and N-MYC FISH
was performed in 18 Non-WNT/SHH subgroup tumors;
high-level amplification of C-MYC was seen in three Non-
WNT/SHH tumors (MB25, MB31 and MB39) while six
tumors displayed increased C-MYC copy numbers due
to gains of chromosome 8, and nine tumors had normal
C-MYC signal (Additional file 2: Table S1). N-MYC ampli-
fication was seen in three Non-WNT/SHH tumors, MB4,
MB37 and MB40 (N-MYC/CEP2 ratio of 1.88, 1.8 and 2.3,
respectively) and four tumors displayed increased N-MYC
signal due to gain of chromosome 2 (Additional file 2:
Table S1). Patient characteristics were available for 15 of
these tumors; 11 out of 15 tumors were from male patients
and patient ages ranged from 1.9 to 8.4 years.
A broad viewing of the GPCR expression patterns heat
map shows that the Non- WNT/SHH tumors reside in
two large tumor groups, interspersed with tumors for
which immunohistochemistry -based subgroup catego-
rization was not possible (Figure 1b). The lowest level
of association clusters together 14 tumor samples; this
cluster of 14 tumor samples corresponds to the GPCR
expression patterns linkage analysis cluster “E.” Nine of
these tumors are of the Non-WNT/SHH subgroup (MB1,
MB3, MB4, MB7, MB14, MB31, MB32, MB39, and MB41)
and the remaining five tumors in this cluster were
uncategorized (MB9, MB10, MB12, MB11 and MB23), as
shown in Figure 1b.
Association clusters “B” and “C” encompass the major-
ity of the remaining non-WNT/SHH tumors (Figure 1b).
One Non-WNT/SHH group tumor (MB40) clustered
with the normal control cerebella samples, and one Non-
WNT/SHH group tumor (MB36) clustered with the SHH
subgroup tumors (Figure 1b). As discussed above, within
one of the second tier clusters, three third tier clusters
emerged (n = 10, 4, 7); the third tier cluster of four tumors
was comprised entirely of Non-WNT/SHH tumors
(MB25, MB26, MB28, MB29) and corresponds to linkage
analysis cluster “B” (Figure 1b and Table 1), while the third
tier cluster of ten tumors was comprised of six Non-
WNT/SHH tumors (MB13, MB15, MB30, MB33, MB37
and MB42) and four immunohistochemically uncatego-
rized tumors (MB15, MB17, MB20, MB22) and correlates
to cluster “C”. GPCR expression data was not available for
one Non-WNT/SHH subgroup tumor (MB27) due to
insufficient quality of mRNA.
When comparing GPCR expression levels between the
Non-WNT/SHH subgroup tumors and the normal con-
trol cerebella, 31 GPCRs displayed significantly altered
expression levels (p ≤ 0.05; Additional file 3: Table S2).
Twelve of these GPCRs were over-expressed in Non-
WNT/SHH tumors compared to control; level of over-
expression ranged from 2.8-fold (OR2A4) to 164-fold
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altered GPCRs ranged from 0.0018-fold (GPR147) to
0.23-fold (EDG8).
Independent correlation of GPCR expression patterns
Analysis of previously published gene expression pro-
filing data from three independent cohorts of medul-
loblastoma patients (Toronto, Boston and Heidelberg
series [8,10,11], respectively), clearly demonstrates that
the GPCR expression patterns observed in our data set
hold consistent in the larger cohorts. For example, in two
cohorts of subtyped medulloblastoma tumors (188 medul-
loblastomas and 11 control cerebella [8], and 103 medullo-
blastomas [10]), both LGR5 and GPR64 were found to be
expressed at higher levels in the WNT subgroup tumors, as
compared to both normal cerebella and the other three
subgroups of tumors (Figure 3a-d); these expression charac-
teristics support our results (Additional file 3: Table S2).
Furthermore, we found PTGER4 to be uniquely over-
expressed in the SHH subgroup of medulloblastoma
(16-fold, p = 0.02; Additional file 3: Table S2) and this
finding replicated what was also seen in the Boston and
Heidelberg tumor cohorts (Figure 3e, g) [8,11]. PTGER4
expression in the SHH subgroup was increased in com-
parison to its expression in Group 3 and Group 4 tu-
mors (t-probabilities = 1.6e-6, 2.7e-8, respectively), but
not WNT tumors, in the Toronto series of medulloblas-
toma patients (Figure 3f ) [10]. Likewise, F2R and FZD2,
both of which were found to be significantly over-
expressed in all subgroups of medulloblastoma tumors in
our dataset (Additional file 3: Table S2), were also both
highly expressed in all tumor groups in previously pub-
lished larger tumor cohorts (Figure 4) [8,10,11].
Discussion
The primary goal of this project was to identify G-protein
coupled receptors that could serve as targets for imaging
and therapeutic agents in medulloblastoma, and this
has been successful. GPCR expression patterns also
have the potential to elucidate initiating and proliferative
mechanisms. The results of this study indicate that GPCR
expression patterns delineate five groups of medulloblas-
toma tumors, two of which correlate with high fidelity to
the WNT and the SHH subgroups of medulloblastoma
[5,7,10,14,17,18,32]. Distinct GPCRs are uniquely over-
expressed in the WNT and SHH subgroups, as well as in
three other groups of tumors, strongly suggesting that
GPCR targets specific to each medulloblastoma subgroup
can be identified. Additionally, these data indicate that the
unique GPCR expression patterns found may help clarify
important mechanistic differences between the groups.
Development of new, or utilization of known ligands
to uniquely over-expressed GPCRs offer the potential to
provide patient specific information. Subgroup targetedimaging, using radiolabeled GPCR ligands, would offer a
non-invasive method to simultaneously diagnose medul-
loblastoma and characterize molecular subgroups. Im-
portantly, targeted imaging would also afford a sensitive
technique for follow-up imaging to determine response
to therapy and the presence of metastatic lesions. A bene-
fit in developing imaging agents targeting over-expressed
receptors is that the downstream action of the targeted
receptor need not correspond to specific tumorigenesis
mechanisms. Rather, the viability of an imaging agent is
dependent on the following criteria: high affinity and spe-
cificity for the target receptor, reliably and highly differen-
tial expression of the target receptor between tumor and
normal tissue, limited off-target or off-tissue effects, and
size constraints. In regard to medulloblastoma, the ability
to cross the blood–brain barrier is also crucial. The utility
of such a GPCR-targeted imaging modality has already
been proven: The Octreoscan, which employs SPECT im-
aging to detect radiolabeled somatostatin receptor ana-
logues has the ability to differentiate medulloblastoma
from low-grade cerebellar tumors and provides an im-
aging modality to differentiate recurrent medulloblastoma
from scar tissue, as well as to localize metastatic lesions
[24,25,28]. Positron emission tomography (PET) imaging
provides a higher degree of sensitivity than SPECT im-
aging [28] and somatostatin receptor targeted agents are
being adapted for use with PET imaging [28]. Recent evi-
dence has shown that high expression of somatostatin
receptors, particularly in non-SHH subgroup tumors, is
correlated to an increased survival and may have potential
as a prognostic marker [36]. However, previous studies re-
port that somatostatin receptor expression is uniformly
high in all medulloblastoma tumors [37,38]. Though these
studies were performed prior to the advent of medullo-
blastoma subgrouping, they indicate that somatostatin
receptor targeted agents will fail to distinguish between
the subgroups of medulloblastoma. Somatostatin recep-
tor, type 2, expression trends towards over-expression in
all subgroups, however does not reach significance in
our current data set (WNT subgroup: 7.6-fold, p = 0.24;
SHH subgroup: 5.1-fold, p = 0.34; Non-WNT/SHH:
8.1-fold, p = 0.23).
GPCR-targeted therapeutics, either radioablative or
chemically based, have the potential to reduce the need
for external beam radiation, and the highly toxic effects
associated with cranial spinal radiation treatment [2].
Therapeutically, GPCR antagonists represent the most
instinctive approach to counteracting the proliferative
signals transduced by some GPCRs within the context of
cancer [39]. As such, GPCR antagonists have previously
been investigated as potential chemotherapeutic targets in
a variety of malignancies [39]. Our data indicate that drugs
targeting specific GPCRs may not display the same effi-
cacy in all medulloblastoma tumors, and that subgroup
Figure 3 Gene expression profiling data from large cohorts of medulloblastoma tumors qualitatively support our results. In our data
set, LGR5 was uniquely over-expressed (120-fold, p =0.01) in the WNT subgroup of tumors compared to normal cerebellum. Over-expression
of LGR5 in WNT tumors has been demonstrated in two previously published sets of gene profiling data (a, b) [8,10]. Our data demonstrate
over-expression of GPR64 in the WNT subgroup of tumors (2200-fold, p = 0.04). This aberration was also reported for WNT tumors in the Boston
and Toronto series (c, d) [8,10]. PTGER4 was uniquely over-expressed in the SHH subgroup of tumors in our data set (16-fold, p = 0.02). This
pattern of expression was also observed in the Boston and Heidelberg series (e, g) [8,11]; in the Toronto series (f) [10], the SHH subgroup shows
increased PTGER4 expression as compared to Group 3 and Group 4 tumors, but not compared to the WNT subgroup. Blue boxes represent WNT
tumors, red boxes represent SHH tumors, yellow boxes represent Group 3 tumors and green boxes represent Group 4 tumors (a, b, c, d, e, f, g).
In the Boston series (a, c, e), the grey boxes represent normal cerebellar controls.
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Figure 4 Gene expression profiling data from large cohorts of medulloblastoma tumors qualitatively support our results. Both FZD2
and F2R were significantly over-expressed in all subgroups of medulloblastoma tumors in our cohort (Additional file 3: Table S2). Three previously
published sets of gene profiling data [8,10,11] found the same pattern to be true for both FZD2 (a, b, c) and F2R (d, e, f). Blue boxes represent
WNT tumors, red boxes represent SHH tumors, yellow boxes represent Group 3 tumors and green boxes represent Group 4 tumors (a, b, c, d, e, f).
In the Boston series (a, d), the grey boxes present normal cerebellar controls.
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cial outcomes. GPCR targeted radiotherapy, in which an
isotope, such as lutetium-177 or yttrium-90, is attached to
a receptor ligand, antibody or other molecule in order to
target the radioactivity to the desired GPCR, has been suc-
cessful in the treatment of neuroendocrine tumors and
other malignancies [40,41].
While each of the differentially expressed GPCRs in our
data set deserves active investigation into its potential as a
target, several candidate receptors are outlined below.
Twenty-six GPCRs exhibited significantly altered expres-
sion levels in the WNT subgroup tumors; thirteen of these
were unique to the WNT subgroup, and eight of these
thirteen displayed overexpression, as compared to normal
cerebella, and thus are candidate receptors for targeting.
Leucine-rich repeat containing G-protein-coupled receptor
5 (LGR5) is significantly over-expressed in the WNT
subgroup of tumors (120-fold, p =0.01); additionally, our
data suggest that it is mildly under-expressed in other
groups of medulloblastoma, providing the benefit of being
highly differentially expressed not only between WNTtumors and normal cerebella, but also between WNT tu-
mors and other medulloblastoma groups (Additional file 3:
Table S2; Figure 3). Furthermore, LGR5 holds the intuitive
advantage of being involved in the WNT signaling pathway;
LGR5, a known marker of certain adult stem cells, forms a
complex with Frizzled/LRP and acts to potentiate the
WNT signal [42]. The role of LGR5 in cancer biology has
been well-described, especially in the realm of gastrointes-
tinal cancers, where antibodies to LGR5 can be used to
identify colorectal cancer stem cells [43,44]. Recently,
R-spondins, a class of four large, secreted proteins known
to enrich WNT signaling, have been identified as high
affinity ligands for LGR5 (and LGR4) [45]. R-spondin pro-
teins hold limited potential as imaging or therapeutic
agents in medulloblastoma due to their large size (35 kDa)
[46] and likely inability to cross the blood–brain barrier
[47,48]. However, the emergence of high-throughput
screening facilities provides the resources to potentially
identify key binding elements of the R-spondin proteins.
Our data suggest that the development of small-molecule
agents targeting the LGR5 receptor is worthy of attention.
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file for a WNT subgroup target (2200-fold, p = 0.04;
Additional file 3: Table S2, Figure 3). GPR64 is an or-
phan receptor that belongs to a family of adhesion pro-
teins and is normally highly expressed only in the
epididymis; however it has recently been found to be
expressed in Ewing’s sarcoma (ES), as well as other car-
cinomas, and represents a marker of invasiveness and
metastatic potential in ES [49]. The exact signaling
mechanism that follows GPR64 activation is yet un-
known and a direct connection between GPR64 and
WNT signaling is not readily apparent; however, the de-
velopment of imaging and radiotherapeutic targets is not
dependent on the role of downstream mechanisms in
proliferation or apoptosis. Due to its differential expres-
sion in medulloblastomas, as well as the fact that it is
normally only expressed in the epididymis, GPR64 rep-
resents a promising candidate for the development of
imaging or radiotherapeutic agents that could be poten-
tially efficacious not only in WNT subgroup medullo-
blastomas, but also Ewing’s sarcoma.
PTGER4 is a GPCR that was uniquely over-expressed
(16-fold, p = 0.02) in the SHH group of tumors
(Additional file 3: Table S2). It was also over-expressed
in “Cluster C” GPCR-grouped medulloblastomas (5.66-fold,
p = 0.01; Table 1), however these tumors fell into the
Non-WNT/SHH subgroup and the same pattern of
PTGER4 expression was not seen in that subgroup as a
whole. PTGER4, or EP4, is a receptor for prostaglandin E2
(PGE2). PGE2 has been shown to act as a growth promot-
ing molecule that stimulates proliferation, angiogenesis
and invasion [50], and is present at high levels in a variety
of malignancies [51,52]. Furthermore, the role of PGE2,
and its receptors, has been investigated within the context
of medulloblastoma [53]. PGE2 induces medulloblastoma
cell proliferation in vitro, while inhibition of PGE2 activity
was suppressive both in vitro and in vivo [53]. While
Baryawno and colleagues [53] found that PGE2 receptors
EP1-3 were most important in stimulating medulloblastoma
cell growth, our data suggest that tumor subgrouping may
affect PGE2’s role. Small molecule antagonists to EP4 are
currently in development for the treatment of inflamma-
tory pain [54]; EP4 represents a particularly viable thera-
peutic target, as blockage at this site does not interfere
with the production of other important prostanoids, and
thus avoids the cardiovascular side effects that can be seen
with blockage of this pathway [54]. EP4 represents a viable
potential target in medulloblastoma, a possibility that is
furthered by the fact that inhibition of the prostaglandin
cascade has been shown to enhance the cytotoxic effects of
radiotherapy [35] presenting the possibility of synergistic
combination therapy. Interestingly, PGE2 has been shown
to potentiate the WNT signaling cascade, both in colo-
rectal cancer cells [34], as well as in normal adulthematopoietic stem cells [55], and it was recently found
that PGE2 upregulates LGR5 [43]. This finding highlights
the important crosstalk between the WNT and SHH sig-
naling cascades [56].
While over-expressed GPCRs provide potential targets,
their under-expressed counterparts are equally pertinent
when probing unanswered mechanistic questions. GPCRs
are responsible for initiating intracellular signaling for
multiple pathways; these receptors act at the cell surface to
integrate and coordinate diverse communicative stimuli
between cells, and converge on shared downstream modu-
lators and effectors. Identifying GPCRs down-regulated
in medulloblastoma subgroups may pinpoint receptors
critical for growth suppression or inhibition, whose under-
expression can lead to, or potentiate, the development of
cancer. Less is known about the initiating mechanisms at
play in Groups 3 and 4 medulloblastomas [7]; identifying
differentially under-expressed GPCRs may help identify
additional pathways that contribute to tumorigenesis in
these subgroups. MTNR1A, a GPCR for melatonin, is sig-
nificantly under-expressed only in the Non-WNT/SHH
group of medulloblastoma tumors (0.0065-fold, p = 0.02).
Melatonin has been postulated to be a tumor suppressor
gene due to its oncostatic effect in various cancers
[33,57,58], as such, expression of MTNR1A was found to
be frequently silenced through methylation of CpG islands
surrounding the MTNR1A promoter in cases of oral squa-
mous cell carcinoma (OSCC) and other primary cancers
[59]. Furthermore, forced expression of MTNR1A in cells
led to growth suppression, suggesting that loss of MTNR1A
activity plays a role in the pathogenesis of OSCC [59];
similar results have also been found in breast cancer cell
lines [60] and in prostate epithelial cells [61]. The anti-
proliferative effect observed in prostate epithelial cells was
demonstrated to be due to MTNR1A-mediated activation
of protein kinase A (PKA) and protein kinase C (PKC) with
a subsequent increase in p27 (kip1) gene transcription. The
p27 gene encodes for cyclin-dependent kinase inhibitor
1B, a protein that prevents the activation of cyclin
E-CDK2 or cyclin D-CDK4 complexes, thus regulating
cell cycle progression. A similar mechanism may be at play
in Non-WNT/SHH medulloblastomas.
Another GPCR, the adenosine A1 receptor (ADORA1)
has a known role in growth suppression [62,63]. In colon
cancer cells, adenosine, via ADORA1, induces apoptosis
by activating caspases [63]. Additionally, it has been
reported that deletion of ADORA1 leads to an increase
in glioblastoma tumor growth, however this observed ef-
fect was believed to be mediated through tumor-adjacent
microglia [64]. ADORA1 was under-expressed in the Non-
WNT/SHH group (0.088-fold, p = 0.03), again suggesting
that loss of ADORA1 activity may play a role in the patho-
genesis of a Non-WNT/SHH medulloblastoma tumors,
especially those seen in Cluster “E” (Table 1).
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cantly altered in subgroups of medulloblastoma; while
many of these alterations reach significant levels, a limita-
tion of our study was the restricted sample size available.
To partially alleviate this concern, we worked with the
Medulloblastoma Advanced Genomics International Con-
sortium (MAGIC), an international consortium that aims
to stratify and characterize medulloblastoma through gen-
omics. Our key findings, specifically the over-expression
of LGR5 and GPR64 in the WNT subgroup tumors and
F2R and FZD2 in all medulloblastoma, were mirrored in
three independent international cohorts of subgrouped
medulloblastoma (Figures 3 and 4). Though our data can-
not be quantitatively combined with these larger data sets,
a qualitative comparison adds substantial confidence and
weight to our results.
Conclusions
In summary, this study has shown that GPCR expres-
sion patterns differentiate the WNT and SHH sub-
group of tumors. We have identified under-expressed
GPCRs that may aid in discerning additional tumor- initi-
ating, or potentiating, pathways at play in medulloblas-
toma. And importantly, we have pinpointed uniquely
over-expressed GPCRs that hold potential as both imaging
and therapeutic targets in the WNT and SHH medullo-
blastoma subgroups.
Additional files
Additional file 1: Figure S1. GPCR expression patterns delineate
distinct groups of medulloblastoma tumors. The heat map represents
GPCR expression levels in 41 medulloblastoma tumors compared to
normal cerebella. This heat map is the same as is seen in Figure 1, with
GPCR names included along the y-axis. Control cerebella are outlined in
the black box.
Additional file 2: Table S1. Additional medulloblastoma tumor
characteristics.
Additional file 3: T3able S2. GPCR expression levels by subgroup,
compared to normal cerebella.
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